Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer
Johanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
Michael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
D Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer
D Andrew Loblaw, David S Mendelson, James A Talcott, et al.
British Journal of Clinical Pharmacology
|
February 14, 2015
Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function
Lot A Devriese, Petronella Els O Witteveen, Marja Mergui-Roelvink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
Geoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer
Johanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors
Michael S Gordon, Christopher S Sweeney, David S Mendelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
D Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer
D Andrew Loblaw, David S Mendelson, James A Talcott, et al.
British Journal of Clinical Pharmacology
|
February 14, 2015
Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function
Lot A Devriese, Petronella Els O Witteveen, Marja Mergui-Roelvink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
Geoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Page
of 5